Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA056457-03
Application #
2097321
Study Section
Special Emphasis Panel (SRC (50))
Project Start
1992-08-01
Project End
1997-07-31
Budget Start
1994-08-01
Budget End
1997-07-31
Support Year
3
Fiscal Year
1994
Total Cost
Indirect Cost
Name
National Cancer Institute
Department
Type
DUNS #
City
Genoa
State
Country
Italy
Zip Code
Puntoni, Matteo; Zanardi, Silvia; Branchi, Daniela et al. (2007) Prognostic effect of DNA aneuploidy from bladder washings in superficial bladder cancer. Cancer Epidemiol Biomarkers Prev 16:979-83
Serrano, Davide; Baglietto, Laura; Johansson, Harriet et al. (2005) Effect of the synthetic retinoid fenretinide on circulating free prostate-specific antigen, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 levels in men with superficial bladder cancer. Clin Cancer Res 11:2083-8
Torrisi, R; Mezzetti, M; Johansson, H et al. (2000) Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-i, IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial. Int J Cancer 87:601-5
Baglietto, L; Torrisi, R; Arena, G et al. (2000) Ocular effects of fenretinide, a vitamin A analog, in a chemoprevention trial of bladder cancer. Cancer Detect Prev 24:369-75
Decensi, A; Torrisi, R; Bruno, S et al. (2000) Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point. Cancer Epidemiol Biomarkers Prev 9:1071-8
Decensi, A; Torrisi, R; Gozza, A et al. (1999) Effect of fenretinide on bone mineral density and metabolism in women with early breast cancer. Breast Cancer Res Treat 53:145-51
Bruno, S; Torrisi, R; Costantini, M et al. (1999) Assessment of DNA flow cytometry as a surrogate end point biomarker in a bladder cancer chemoprevention trial. J Cell Biochem 76:311-21
Decensi, A; Torrisi, R; Fontana, V et al. (1998) Correlation between plasma transforming growth factor-beta 1 and second primary breast cancer in a chemoprevention trial. Eur J Cancer 34:999-1003
Torrisi, R; Parodi, S; Fontana, V et al. (1994) Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid fenretinide in breast cancer patients. Cancer Epidemiol Biomarkers Prev 3:507-10
Torrisi, R; Pensa, F; Orengo, M A et al. (1993) The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients. Cancer Res 53:4769-71